hepat
c
viru
hcv
vaccin
candid
induc
hcvspecif
immun
respons
may
protect
naiv
chimpanze
heterolog
experiment
challeng
howev
mechan
behind
protect
remain
although
inform
regard
immun
correl
protect
immun
incomplet
suffici
evid
point
toward
pivot
role
potent
function
cellular
immun
respons
sever
hcv
vaccin
strategi
induc
strong
cellular
immun
mice
rhesu
macaqu
human
often
combin
prime
immun
system
booster
immun
use
dna
recombin
viral
vector
includ
adenoviru
modifi
viru
ankara
mva
preclin
evalu
potenti
efficaci
hcv
vaccin
candid
limit
chimpanze
human
mous
sever
hcv
vaccin
candid
creat
includ
viral
vector
typic
encod
multipl
target
antigen
reli
preclin
immunogen
studi
nonhuman
primat
rhesu
comparison
differ
vector
regimen
nonhuman
primat
highli
valuabl
hcv
vaccin
develop
shed
light
factor
specif
influenc
hcv
vaccin
immunogen
well
provid
technolog
improv
field
genet
vaccin
perform
hiv
recent
studi
hcv
adenoviru
vaccin
boost
induc
robust
cellular
respons
hcv
pseudoparticl
enhanc
humor
respons
poxviru
prime
induc
humor
cellular
respons
immun
respons
optim
heterolog
primeboost
vector
includ
plasmid
dna
recombin
sfv
replicationincompet
adenoviru
poxviru
mva
encod
structur
hcv
antigen
core
c
two
envelop
glycoprotein
nonstructur
antigen
develop
evalu
immunogen
mice
alon
variou
primeboost
combin
vector
success
elicit
cellular
humor
immun
respons
includ
moreov
dnadnamvamva
vaccin
regimen
induc
robust
immun
respons
associ
earli
control
heterolog
hcv
infect
present
studi
explor
b
tcell
immun
respons
induc
vaccin
rhesu
macaqu
investig
whether
two
differ
immun
regimen
investig
date
potenti
improv
hcvspecif
immun
respons
dna
follow
adenoviru
sfv
follow
mva
character
immun
respons
four
vaccin
antigen
induc
three
regimen
rhesu
macaqu
evalu
predict
valu
rhesu
macaqu
model
hcv
vaccin
immunogen
compar
immun
respons
observ
rhesu
macaqu
dnamva
observ
chimpanze
exact
dnamva
vaccin
three
regimen
test
three
group
four
anim
figur
group
receiv
dna
vaccin
twice
follow
two
immun
group
ii
receiv
dna
vaccin
twice
follow
two
immun
mva
group
iii
receiv
rsfv
vaccin
twice
follow
two
immun
mva
hcvspecif
lymphoprolif
respons
test
use
recombin
protein
core
genotoyp
genotyp
respons
induc
two
dna
sfv
inject
figur
individu
stimul
index
si
cumul
four
antigen
direct
mainli
c
figur
top
pie
chart
supplementari
figur
signific
differ
observ
dna
dd
group
sfvimmun
ss
anim
lymphoprolif
respons
clearli
boost
mva
immun
similar
high
level
figur
cumul
si
analysi
contribut
individu
hcv
vaccin
antigen
show
ad
mva
boost
lymphoprolifer
domin
individu
si
rang
supplementari
figur
combin
ssmm
sfvmva
induc
significantli
higher
prolifer
averag
si
compar
vaccin
averag
si
dnaprim
group
supplementari
figur
enumer
c
genotyp
genotyp
induc
secret
respect
repres
cytokin
figur
although
cell
separ
peripher
blood
mononuclear
cell
pbmc
enzymelink
immunospot
elispot
assay
perform
recombin
protein
stimulu
therefor
respons
detect
presum
repres
mainli
immun
either
dna
sfv
lymphoprolifer
detect
margin
cytokin
product
induc
anim
mount
detect
respons
low
level
respons
detect
spot
form
unit
sfu
million
cell
respect
antigen
data
shown
differ
observ
group
shown
booster
immun
mva
three
regimen
induc
strong
hcvspecif
product
anim
number
specif
produc
cell
rang
sfumillion
cell
figur
statist
differ
three
group
figur
four
antigen
contribut
respons
figur
pie
chart
supplementari
figur
statist
signific
differ
observ
group
even
appar
higher
cspecif
respons
observ
sfvmva
inject
appar
higher
respons
group
ddaa
also
statist
signific
due
high
variabl
respons
group
supplementari
figur
contrast
similarli
lymphoprolif
respons
two
mva
inject
ssmm
induc
significantli
higher
respons
averag
sfumillion
cell
compar
vaccin
strategi
averag
sfumillion
cell
ddaa
ddmm
group
respect
supplementari
figur
number
hcvspecif
secret
cell
detect
mva
inject
lower
rang
sfumillion
cell
equival
group
figur
four
antigen
contribut
hcvspecif
respons
three
group
figur
pie
chart
supplementari
figur
howev
sfvmva
regimen
ssmm
induc
significantli
higher
respons
supplementari
figur
mva
boost
anim
elicit
respons
overal
lower
respons
sfumillion
cell
figur
regim
induc
lower
respons
two
regimen
involv
mva
respons
c
vaccin
antigen
contribut
respons
except
c
ddaa
group
sfvmva
vaccin
anim
elicit
significantli
higher
respons
supplementari
figur
addit
dnamva
induc
significantli
higher
respons
regimen
supplementari
figur
taken
togeth
result
demonstr
three
primeboost
vaccin
regimen
abl
induc
c
tcell
respons
mva
inject
includ
higher
product
figur
notabl
anim
receiv
two
boost
induc
lower
respons
compar
group
boost
mva
suggest
stronger
bia
figur
group
immun
sfvmva
regimen
elicit
higher
lymphoprolifer
cytokin
respons
compar
two
vaccin
combin
elispot
also
perform
overlap
peptid
cover
genotyp
j
strain
use
vaccin
vector
peptid
pool
pp
contain
peptid
aa
peptid
cover
aa
cover
aa
use
three
anim
mount
detect
peptidespecif
respons
dna
inject
none
respond
sfv
inject
data
shown
low
respons
ddaa
ddmm
wane
week
week
post
last
dna
inject
figur
contrast
booster
inject
induc
peptidespecif
respons
anim
sfumillion
cell
figur
mva
induc
lower
peptidespecif
respons
anim
dnamva
group
anim
sfvmva
group
figur
mva
boost
induc
high
respons
anim
rang
sfumillion
cell
respons
dnamvaimmun
anim
sfvmva
regimen
figur
respons
remark
similar
group
total
level
figur
kinet
figur
contribut
nand
ctermin
end
protein
figur
capac
three
differ
primeboost
combin
induc
hcv
envelopespecif
bcell
respons
analyz
elisa
use
recombin
protein
genotyp
neutral
assay
virtual
antibodi
respons
detect
time
point
figur
contrast
antibodi
respons
detect
three
group
figur
dna
sfv
inject
poor
induc
antibodi
respons
two
inject
strong
respons
elicit
four
anim
previous
prime
dna
figur
c
littl
antibodi
respons
gener
eight
anim
receiv
mvaboost
inject
figur
none
sera
neutral
activ
pseudoparticl
assay
data
shown
use
pseudoparticl
homolog
hyper
variabl
region
contain
neutral
epitop
supplementari
figur
studi
immunogen
three
hcv
primeboost
vaccin
regimen
evalu
nonhuman
primat
dna
compar
sfv
immun
follow
immun
either
adenoviru
mva
rhesu
macaqu
vaccin
regimen
induc
ifngamma
tcell
respons
regim
induc
antibodi
respons
envelop
protein
sfvmva
induc
stronger
tcell
respons
comparison
dna
sfv
conclus
lymphoprolif
respons
induc
anim
limit
subset
anim
elicit
detect
antigenspecif
cytokin
respons
dna
sfv
prime
dna
immun
may
provid
optim
prime
use
specif
formul
deliveri
devic
electropor
would
induc
superior
notabl
higher
lymphoprolifer
cytokin
product
induc
mva
boost
group
immun
sfvmva
compar
dnamva
indic
sfv
prime
respons
effect
even
though
lead
antibodi
respons
group
could
due
differ
construct
rather
deliveri
vector
technic
reason
gene
insert
express
sfv
particl
oppos
combin
dna
adenoviru
mva
vector
therefor
differ
may
due
differ
level
antigen
express
vector
whether
antigen
present
cell
surfac
combin
express
three
antigen
vector
may
compromis
independ
express
process
present
within
antigen
present
cell
question
address
studi
includ
boost
superior
mva
dna
prime
rhesu
macaqu
immun
respons
predict
protect
hcv
respons
observ
chimpanze
challeng
hcv
regard
boost
potenti
tcell
respons
rel
similar
dnamva
group
trend
observ
indic
higher
prolifer
mvaboost
higher
respons
group
statist
signific
absenc
signific
differ
may
due
low
number
anim
per
group
limit
direct
consequ
work
nonhuman
primat
addit
respect
immunogen
adenoviru
mva
vaccin
may
partial
antigen
depend
effect
antigen
immunomodulatori
properti
may
also
influenc
cytokin
microenviron
induc
vector
exampl
mva
compar
context
antigen
found
superior
poxvirus
induct
tcell
respons
malaria
mva
encod
mtb
antigen
induc
stronger
produc
cell
bcg
three
vaccin
strategi
induc
immun
respons
respons
larg
exceed
respons
strike
differ
observ
howev
lower
respons
anim
reveal
bia
howev
mva
shown
induc
antibodi
respons
differ
antigen
bloodstag
studi
vector
induc
strong
transient
antibodi
respons
one
two
envelop
protein
agreement
recent
hcv
vaccin
develop
demonstr
capac
adenoviru
boost
support
envelopespecif
confirm
caution
taken
tri
use
result
differ
immunogen
influenc
design
vaccin
diseas
howev
antibodi
respons
elicit
immun
studi
neutral
shortliv
mayb
induc
antibodi
mask
neutral
epitop
recent
absenc
function
activ
persist
antibodi
use
viral
vector
also
previous
studi
offer
uniqu
opportun
compar
immun
respons
elicit
dnamva
regimen
rhesu
macaqu
chimpanze
exact
construct
regimen
use
immun
four
chimpanze
immun
induc
robust
multispecif
immun
respons
four
anim
follow
exposur
associ
drastic
reduct
peak
viremia
rna
level
liver
acut
phase
infect
vaccin
regimen
induc
respons
detect
elispot
similar
pattern
one
observ
rhesu
macaqu
strong
ifn
respons
lower
respons
especi
contrari
rhesu
macaqu
howev
chimpanze
mount
potent
respons
number
antigenspecif
produc
cell
compar
number
produc
cell
three
four
strike
differ
two
primat
speci
dnamva
regim
induc
robust
antibodi
respons
chimpanze
possibl
stronger
respons
observ
chimpanze
support
potent
bcell
respons
reason
differ
unknown
respons
absent
rhesu
macaqu
lower
respons
underlin
difficulti
predict
immunogen
specif
vaccin
regim
base
one
primat
speci
unravel
rel
contribut
cellular
humor
immun
prevent
acut
chronic
diseas
avail
highli
effici
antivir
drug
treatment
abl
cure
larg
proport
hcv
infect
relev
cost
hcv
vaccin
develop
question
howev
treatment
extrem
expens
particularli
develop
countri
thu
vaccin
prevent
treat
hcv
infect
still
indic
high
preval
strong
restrict
research
involv
chimpanze
restrict
efficaci
studi
expens
phase
ii
clinic
trial
becom
possibl
evalu
efficaci
vaccin
candid
therefor
studi
identifi
approach
optim
investig
predict
valu
nonhuman
primat
highli
relev
context
twelv
outbr
purpos
bred
naiv
male
rhesu
macaqu
macaca
mulatta
year
old
import
china
seroneg
adenoviru
preponder
genu
includ
serotyp
poxvirus
igg
antivaccinia
viru
igg
select
follow
comprehens
health
check
randomli
assign
three
group
studi
experiment
procedur
approv
local
anim
ethic
use
committe
perform
accord
dutch
intern
standard
use
anim
scienc
serum
pbmc
isol
blood
sampl
collect
regular
time
point
sedat
use
asept
techniqu
becton
dickinson
breda
netherland
vacutain
system
blind
bodi
weight
temperatur
hematolog
biochemistri
valu
monitor
routin
interv
gene
insert
encod
protein
c
base
genotyp
j
strain
hcv
genbank
vector
use
immun
describ
vector
encod
dna
sfv
describ
plasmid
obtain
insert
aa
gene
sequenc
pgwiz
gene
therapi
system
inc
san
diego
ca
usa
describ
sfvc
particl
prepar
insert
correspond
fragment
isol
pcr
sfv
express
vector
packag
recombin
rna
sfv
product
hcv
protein
rsfv
particl
confirm
immunofluoresc
vitro
transfect
bhk
cell
metabol
label
pulsechas
immunoprecipit
follow
sdspage
data
shown
sfvcore
mix
immun
express
human
type
replicationdefect
adenoviru
describ
human
adenoviru
serotyp
chosen
prototyp
adenoviru
studi
recombin
vector
construct
transient
host
rang
select
use
structur
amino
acid
aa
nonstructur
aa
gene
respect
previous
vector
use
immun
transgen
describ
figur
c
polypeptid
aa
helicas
aa
deriv
hcv
genotyp
express
e
coli
purifi
ninta
column
describ
envelop
protein
delet
transmembran
domain
deriv
sequenc
clone
ptalpha
vector
describ
fifteenm
peptid
overlap
seven
amino
acid
cover
c
sequenc
genotyp
j
purchas
clonestar
biotech
brno
czech
republ
immun
dna
rsfv
consist
two
inject
week
mva
administ
week
figur
dna
immun
mg
mg
dissolv
salin
buffer
equal
divid
administ
intramuscularli
intraderm
sfv
immun
pfu
construct
dissolv
salin
inject
subcutan
sc
anim
group
boost
subcutan
twice
pfu
construct
anim
group
ii
iii
boost
twice
pfu
mva
construct
administ
intramuscularli
intraderm
construct
mix
c
construct
inject
left
side
right
therefor
vaccin
vector
administ
via
differ
rout
rout
vector
select
induc
strongest
immun
respons
rout
may
impact
magnitud
qualiti
result
immun
respons
aim
studi
compar
vector
potenc
singl
rout
identifi
optim
vaccin
regimen
vector
inject
optim
rout
quantif
antiadenoviru
antibodi
perform
frozen
serum
independ
hospit
laboratori
erasmu
rotterdam
netherland
quantit
enzym
immunoassay
serion
elisa
classic
adenoviru
iggiga
detect
antibodi
eight
preponder
genusspecif
epitop
antihcv
antibodi
respons
frozen
sera
measur
use
elisa
hcv
c
mg
protein
mg
elisa
perform
describ
experi
cutoff
determin
mean
valu
plu
three
time
standard
deviat
obtain
serum
three
random
naiv
serum
sampl
capac
frozen
sera
neutral
hcv
analyz
use
hcv
pseudoparticl
glycoprotein
strain
infect
assay
target
cell
previous
control
neutral
perform
use
pseudoparticl
gener
glycoprotein
deriv
felin
endogen
retroviru
lymphoprolifer
measur
incorpor
previous
describ
use
fresh
result
express
si
calcul
cpm
antigen
divid
cpm
medium
alon
lymphoprolifer
consid
posit
si
exceed
quantif
specif
cytokin
secret
cell
perform
elispot
assay
use
fresh
pbmc
accord
manufactur
instruct
ucytech
utrecht
netherland
use
concanavalin
cona
recombin
protein
peptid
medium
alon
result
express
mean
spot
form
unit
triplic
assay
per
one
million
pbmc
minu
mean
number
spot
obtain
cell
cultur
medium
alon
also
triplic
assay
result
superior
sfcmillion
pbmc
consid
posit
respons
compar
immunogen
differ
vaccin
combin
anova
pvalu
calcul
exact
method
twotail
use
differ
consid
statist
signific
prism
mac
os
x
use
